美国成人慢性疼痛患者4天阿片类药物逐渐减量期间经皮耳迷走神经刺激治疗慢性疼痛和阿片戒断症状的随机假对照试验方案
本研究为单中心、随机、双盲、假对照优效性试验,纳入40例长期阿片治疗的慢性疼痛成人,随机分配至活性经皮耳迷走神经刺激(tAN)组(n=20)或假tAN组(n=20),在4天住院阿片减量期间比较脑功能磁共振成像及戒断量表等指标,以探究tAN的作用机制。
要点
- 纳入18至75岁慢性疼痛成人,过去6个月中疼痛天数超过一半,且愿意将阿片剂量减少至少10%。
- 主要结局为脑功能磁共振成像(fMRI)测量疼痛网络的BOLD信号和静息功能连接(z值)。
- 两组在第1天进行轻度至中度阿片减量,并在住院医疗监督下维持减量水平4天。
核心结论
- 理解tAN的作用机制将有助于未来开发更有效的非药物疗法,以在逐渐减少处方阿片类药物的同时减轻戒断症状。
研究设计与样本
- 单中心、随机、双盲、假对照优效性框架试验,在美国一家大型学术医疗中心住院进行。
- 计划入组40例长期阿片治疗的慢性疼痛成人,随机分配至活性tAN组(n=20)或假tAN组(n=20),按出生性别分层。
- 参与者年龄18至75岁,过去6个月中疼痛天数超过一半,正在接受阿片处方,愿意将阿片剂量减少至少10%,且尿液药物筛查处方的阿片阳性但非法药物和非处方阿片阴性。
主要发现
- 首次受试者入组于2023年7月25日至28日完成。
- 主要结局为脑功能磁共振成像(fMRI)测量疼痛网络的BOLD信号和静息功能连接(z值)。
- 次要结局包括自我报告和临床医生观察的阿片戒断量表、行为评估问卷和定量感觉测试(QST)数据。
关键数值与推荐
- 排除标准包括影响参与安全的情况(如癫痫发作、当前自杀意念、当前非法药物或酒精滥用、妊娠)、妨碍fMRI评估的情况(植入医疗器械、幽闭恐惧症)或影响疼痛药物摄入的状态(如过去一个月手术、阿片处方剂量大于每日200吗啡毫克当量、神经系统疾病或创伤性脑损伤史、活跃的癌症治疗)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reducing opioid use is challenging due to limited evidence-based weaning methods and a lack of interventions to mitigate withdrawal symptoms. An emerging intervention using transcutaneous auricular neurostimulation (tAN) is being developed to reduce opioid withdrawal symptoms, but its mechanisms of action are not yet well understood. This is a clinical trial performed to investigate the mechanisms of tAN in managing pain and opioid withdrawal during opioid taper in adults with chronic pain. METHODS: This is a single-site, randomized, double-blind, and sham-controlled superiority framework trial during an inpatient opioid taper for participants on long-term opioid therapy for chronic pain. Participants are recruited for an inpatient stay at a large, academic medical center in the United States. Included participants are adults between 18 and 75 years of age who have the presence of pain more than half of the days in the past 6 months, are prescribed opioid medication, have a willingness to taper the opioid dose by at least 10%, and have a urine drug screen positive for the prescribed opioid but negative for illicit drugs and nonprescribed opioids. Participants are excluded with a condition affecting their safety of participation (e.g., epileptic seizures, current suicidal ideation, current abuse of illicit drugs or alcohol, pregnancy), a condition that precludes fMRI assessment (implanted medical device, claustrophobia), or a status affecting pain medication intake (e.g., surgery in the past month, opioid prescription dose > 200 morphine milligram equivalents per day, history of neurological diseases or traumatic brain injury, active treatment for cancer). Participants are randomized to receive either active tAN (n = 20) or sham tAN (n = 20). Both groups undergo a mild-to-moderate opioid taper on day 1 and are maintained at the reduced level for 4 days under inpatient medical supervision. The primary outcome measure, brain functional magnetic resonance imaging (fMRI), is used to measure BOLD signals and resting functional connectivity (z-value) of pain networks. Secondary outcome measures are self- and clinician-observed opioid withdrawal scales, behavioral assessment questionnaires, and quantitative sensory testing (QST) data. The first subject enrollment was completed from July 25 to 28, 2023. The total enrollment count was set to 40 with two arms of equal ratios. Randomization stratification by gender at birth was performed. The study physician, intervention-providing staff member, and outcome-assessing study coordinator each perform recruitment, and each is blinded to treatment group assignment. Safety and harm measures of opioid withdrawal will be assessed with the Clinical and Subject-reported Opiate Withdrawal Scores. Vital signs will be assessed three times per day, and adverse events will be recorded and reported as necessary. DISCUSSION: Understanding the mechanisms of action of tAN will lead to the development of more effective future non-pharmacologic treatments in mitigating withdrawal while gradually tapering participants off prescription opioid management. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05555485. Registered on 15 September 2022.
引用
- Pierson CJ, Khodaparast N, McWade MA, et al. The protocol for a randomized, sham-controlled trial of transcutaneous auricular neurostimulation for chronic pain and opioid withdrawal symptoms during a 4-day opioid taper for adults in the United States. Trials. 2025. PMID: 41102821. doi:10.1186/s13063-025-09171-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。